Safety and PK/PD of LY3209590 in Chinese Patients with T2DM

Phase 1, randomised trial of Insulin efsitora alfa in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants with One or More Adverse Events (AEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at Week 12 and Incidence and Severity of Hypoglycemia at Week 12. Started Nov 2022; status: completed.